• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

PPARγ expression in esophageal cancer and effect of PPARγ ligand

Research Project

Project/Area Number 13671363
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionKURUME UNIVERSITY

Principal Investigator

TANAKA Toshiaki  Kurume University School of Medicine, Department of Surgery, Instructor, 医学部, 助手 (20227151)

Co-Investigator(Kenkyū-buntansha) SHINOZAKI Kouji  Kurume University School of Medicine, Department of Surgery, Instructor, 医学部, 助手 (70226140)
YAMANA Hideaki  Kurume University School of Medicine, Department of Surgery, Professor, 医学部, 教授 (30140669)
Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 2002: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
Keywordsesophageal cancer / PPARγ / cell cycle / cell differentiation
Research Abstract

We investigated the expression of peroxisome proliferator-activated receptor (PPAR) γ in human esophageal squamous cell carcinomas and the effect of PPARγ ligand on cell growth in esophageal cancer. Reverse transcription-polymerase chain reaction and Western blot analysis showed that human esophageal cancer cell lines, KE-5, KE-8 and KE-10, expressed PPARγ mRNA and protein. Cell growth of these cells were inhibited after treatment with PPARγ ligand, troglitazone, in a dose-dependent manner. Flow cytometric analysis demonstrated G1 cell cycle arrest and positive rate of Ki-67 staining was significantly decreased after troglitazone treatment. These results suggested that antiproliferative effect of PPARγ ligand in esophageal cancer is in part induced by negative effect on the cell cycle. Involucrin is expressed in squamous epithelial cells and has been used as a standard marker of terminal differentiation of squamous cells. Troglitazone treatment induced increased expression of involucrin in esophageal cancer cells, indicating that PPARγ ligand augmented cell differentiation in esophageal cancer cells. Furthermore, we examined whether PPARγ ligand induced apoptosis in these cells or not. There was no DNA fragmentation observed after troglitazone treatment, meaning that apoptosis was not involved in antiproliferative effect of PPARγ ligand in esophageal cancer. Finally, we examined the effect of troglitazone on tumor growth in vivo. We observed no difference in tumor growth between treated and untreated group.

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi